The global neuropathic pain market was valued at USD 8.5 billion in 2025 and is expected to reach USD 9.1 billion in 2026. The market is projected to expand to USD 15.2 billion by 2033, registering a CAGR of 7.5% from 2026 to 2033. North America dominated the global market in 2025, accounting for 37.9% of revenue, while Asia Pacific is expected to record the fastest growth during the forecast period.

The market is being shaped by the growing worldwide burden of chronic diseases, particularly diabetes and cancer, both of which can contribute to nerve damage and persistent pain. Increasing diagnosis of neuropathic conditions, greater awareness of chronic pain management, and continued development of non-opioid therapies are also expanding treatment opportunities.

What Is Driving Demand for Neuropathic Pain Treatments?

Growing Burden of Diabetes and Nerve Damage

Diabetes is one of the strongest underlying factors supporting demand for neuropathic pain therapies. Diabetic peripheral neuropathy (DPN) can cause persistent burning, tingling, numbness, and pain, particularly in the hands and feet. Rising obesity rates, sedentary lifestyles, aging populations, and dietary changes are contributing to the expanding diabetic population worldwide.

According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20–79 were living with diabetes globally in 2024, with the number expected to approach 853 million by 2050. The expanding diabetic population creates a larger patient pool at risk of developing DPN and associated chronic pain.

Research has also highlighted the scale of the problem. A study published by Nature Publishing Group in April 2025 indicated that neuropathy affected approximately 50% of people with diabetes, with prevalence estimates ranging from 6% to more than 60%. Painful diabetic peripheral neuropathy affected approximately 13% to 35% of patients. In October 2024, research published in Frontiers in Endocrinology evaluated 4,908 patients and identified 1,627 cases of neuropathy, corresponding to a prevalence of 33.2%.

Download a free sample report or claim your copy of this full market intelligence report

Shift Toward Non-Opioid Pain Management

The growing focus on opioid safety and stricter prescribing regulations is encouraging healthcare providers to consider non-opioid approaches. Anticonvulsants, particularly gabapentinoids, as well as antidepressants and topical therapies, remain important treatment options.

Therapies such as pregabalin, gabapentin, and duloxetine are benefiting from continued demand for long-term neuropathic pain management. At the same time, pharmaceutical and medical-device companies are exploring more targeted approaches, including advanced neuromodulation technologies.

Rising Interest in Topical Formulations

Topical therapies are gaining attention because they can provide localized pain relief while potentially limiting systemic exposure. Lidocaine and capsaicin patches and formulations represent important areas of development, particularly for patients seeking localized treatment options or experiencing tolerability concerns associated with systemic medications.

Market Structure: Which Segments Lead?

The market shows distinct patterns across drug class, indication, and administration route.

• Drug class: Anticonvulsants accounted for the largest share, representing 40.66% of the market in 2025.
• Indication: Diabetic peripheral neuropathy led the market with a 34.40% share in 2025, reflecting the growing diabetes burden worldwide.
• Route of administration: Oral therapies represented the leading route of administration in 2025.
• Regional leadership: North America captured 37.9% of global revenue in 2025.
• Fastest-growing region: Asia Pacific is projected to register the highest CAGR between 2026 and 2033.
• Country highlight: The U.S. accounted for the largest national revenue contribution to the neuropathic pain market in 2025.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Regional Outlook

North America remains the leading regional market, supported by high disease awareness, established healthcare infrastructure, widespread availability of neuropathic pain therapies, and significant pharmaceutical activity.

Asia Pacific, however, is positioned for the fastest growth. Expanding diabetic populations in countries such as India and China, improving healthcare access, rising diagnosis rates, and greater awareness of chronic pain management are expected to create substantial opportunities for pharmaceutical manufacturers and healthcare providers.

Competitive Landscape

The neuropathic pain market includes established pharmaceutical companies with portfolios spanning anticonvulsants, analgesics, antidepressants, topical treatments, and other pain-management solutions. Key companies profiled in the market include:

• Pfizer Inc.
• Eli Lilly and Company
• Johnson & Johnson
• Novartis AG
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Grünenthal GmbH

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Explore our dedicated business services:

• S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.